GleamWall
中文EN

AXIM AXIM BIOTECHNOLOGIES, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1514946 · Fiscal year ends 12/31

Financial factors as of 2022-09-30 (2022Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-89.0%
TTM net income YoY-29.0%
TTM EPS YoY282.5%
Revenue 3-yr CAGR-67.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-182,235.4%
Net margin-218,733.8%
FCF margin—
EBITDA margin-142,796.3%

Returns

ROE-10,021.6%
ROA-143.0%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets197.8%
Debt / equity—
Current ratio0.08x
Interest coverage-7.07x

Cash quality & payout

Operating cash flow / net income0.19x
Accruals ratio-116.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2024Q22024-06-302024Q12024-03-312023Q4*2023-12-312023Q32023-09-302023Q22023-06-302023Q12023-03-312022Q4*2022-12-312022Q32022-09-30
Income statement
Revenue$17,479$52,979$12,859$9,581$9,929$7,397$7,561$1,314
Cost of revenue$1,744———$0———
Gross profit$15,735———$9,929——$1,314
R&D expense$4,063$15,495$36,373$34,713$34,074$20,336$44,611$29,722
SG&A expense$472,984$331,040$623,671$456,648$566,829$590,940$998,475$1.18M
Operating income-$569,441-$401,563-$753,940-$588,535-$697,729-$710,634-$1.14M-$1.32M
Interest expense$178,244-$163,597-$734,002$64,658$751,505-$57,839-$1.37M$57,481
Pretax income-$2.27M-$292,299-$1.90M$328,470-$3.72M-$2.76M-$899,050-$2.03M
Income tax$0$0$0$0$0$0$0$0
Net income-$2.27M-$292,299-$1.90M$328,470-$3.72M-$2.76M-$899,050-$2.03M
EBITDA-$461,312-$293,556-$647,185-$481,780-$590,974-$603,879-$1.04M-$1.21M
EPS (basic)-0.01-0.00—0.00-0.02-0.01—-0.01
EPS (diluted)-0.01-0.00—0.00-0.02-0.01—-0.01
Weighted avg. shares (diluted)———478.51M226.26M———
Banking
Noninterest expense——-$690,000$0——-$1.14M$0
Balance sheet
Cash & equivalents$6,044$96,711$156,457$23,220$97,498$53,542$47,282$163,746
Inventory———————$20,089
Current assets$20,243$96,711$156,457$23,220$97,498$56,556$103,979$249,225
PP&E, net$117,993$127,510$134,067$69,410$77,554$85,697$93,840$102,069
Intangibles———$3.69M$3.79M—$3.99M—
Total assets$3.73M$3.93M$4.12M$4.04M$4.25M$4.04M$4.21M$4.48M
Current liabilities$6.57M$4.80M$5.98M$4.28M$8.37M$4.86M$3.39M$3.16M
Short-term debt$92,645$91,306$94,829$91,672$88,475$4,984$19,789—
Long-term debt$93,847$118,031$137,044—————
Total debt$186,492$209,337$231,873—————
Total liabilities$13.26M$11.38M$11.78M$10.00M$14.00M$10.20M$9.04M$8.86M
Shareholders' equity-$9.53M-$7.45M-$7.66M-$5.96M-$9.75M-$6.16M-$4.83M-$4.38M
Net debt$180,448$112,626$75,416—————
Shares outstanding294.46M278.43M245.93M237.65M227.65M223.65M192.44M138.10M
Cash flow statement
Operating cash flow$553,013-$252,506$19,556-$264,503-$643,594-$141,959-$315,505-$321,225
Capital expenditure—$2,839$0———$0$2,710
Free cash flow—-$255,345$19,556———-$315,505-$323,935
Investing cash flow$0-$2,839$0$0$0$0$0-$2,710
Financing cash flow-$643,680$195,599$113,681$190,225$687,550$148,219$199,041$422,518
Depreciation & amortization$108,129$108,007$106,755$106,755$106,755$106,755$106,840$106,744
Stock-based compensation$9,613$9,613$34,086$38,415$21,404$103,822$219,181$517,180

Free plan shows the latest 8 periods; Pro shows all 54 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.